{"entity":{"id":"nct01843374","kind":"trial","name":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","aka":[],"tldr":"A phase 2 trial of Tremelimumab in mesothelioma, run by MedImmune LLC, active and no longer recruiting.","summary":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma is a phase 2 interventional study registered as NCT01843374 by MedImmune LLC, with 571 participants enrolled, started 2013-05-17 and due to reach its primary completion in 2016-01-24. Interventions recorded: Tremelimumab, Placebo. Conditions listed: Unresectable Pleural or Peritoneal Malignant Mesothelioma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01843374","url":"https://clinicaltrials.gov/study/NCT01843374"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mesothelioma","peritoneal-mesothelioma","pleural-mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tremelimumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01843374","phase":"2","setting":"A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma","sponsor":"MedImmune LLC","started":"2013-05-17","startedType":"actual","enrolled":571,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01843374/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}